7Hassfeld W, Steiner G, Hartmunth K, et al.Demonstration of a new antinuelear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum, 1989, 32 : 1515-1520.
8Schellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum, 2000, 43:155-163.
9Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, et al. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol, 2004,33 : 218-220.
10Palosuo T, Tilvis R, Strandberg T, et al. Filaggrin related antibodies among the aged. Ann Rheum Dis, 2003,62:261-263.
1Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing[J]. Rheumatology (Oxford), 2012, 51:721-729.
2Spinel-Bejarano N, Quintana G, Heredia R, et al. Comparative study of elderly-onset rheumatoid arthritis and young-onset rheumatoid arthritis in a Colombian population: clinical, laboratory and HLA- DRB1 findings[J]. Clin Exp Rheumatol, 2013, 31: 40-46.
3Zintzaras E, Papathanasiou A, Ziogas D, et al. The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates[J]. BMC Musculoskelet Disord, 2012, 13 : 113.
4Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative[J]. Ann Rheum Dis, 2010, 69:1580-1588.
5Stuhlmuller B, Ungethum U, Scholze S, et al. Identification of known and novel genes in activated monoeytes from patients with rheumatoid arthritis [J]. Arthritis Rheum, 2000, 43: 775-790.
6Ohyama K, Kawakami A, Tamai M, et al. Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis[J]. Ann Rheum Dis, 2012, 71:1916-1917.
7Wang JG, Xu WD, Zhai WT, et al. Disorders in angiogenesis and redox pathways are main factors contributing to the progression of rheumatoid arthritis: a comparative proteomics study [J] . Arthritis Rheum, 2012, 64:993-1004.
8Rico MC, Castaneda JL, Manns JM, et al. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSPl-derived peptide treatment[J]. J Cell Physiol, 2007, 211:504-512.
9Manns JM, Uknis AB, Rico MC, et al. A peptide from thrombospondin 1 modulates experimental erosive arthritis by regulating connective tissue growth factor [J]. Arthritis Rheum, 2006, 54: 2415-2422.
10Jou IM, Shiau AL, Chen SY, et al. Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis[J].Arthritis Rheum, 2005, 52: 339-344.
